Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner

F.N.U. Apoorva,1 Ye F. Tian,1 Timothy M. Pierpont,2 David M. Bassen,3 Leandro Cerchietti,4 Jonathan T. Butcher,3 Robert S. Weiss,2 Ankur Singh1,3*

1Sibley School of Mechanical and Aerospace Engineering, College of Engineering, Cornell University, Ithaca, New York
2Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York
3Meinig School of Biomedical Engineering, College of Engineering, Cornell University, Ithaca, New York
4Division of Hematology and Medical Oncology, Weill Cornell Medical College of Cornell University, New York, New York

Received 17 October 2016; revised 16 December 2016; accepted 10 January 2017
Published online 12 April 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/jbm.a.36031

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma, with multiple molecular subtypes. The activated B-cell-like DLBCL subtype accounts for roughly one-third of all the cases and has an inferior prognosis. There is a need to develop better class of therapeutics that could target molecular pathways in resistant DLBCLs; however, this requires DLBCLs to be studied in representative tumor microenvironments. The pathogenesis and progression of lymphoma has been mostly studied from the point of view of genetic alterations and intracellular pathway dysregulation. By comparison, the importance of lymphoma microenvironment in which these malignant cells arise and reside has not been studied in as much detail. We have recently elucidated the role of integrin signaling in lymphomas and demonstrated that inhibition of integrin-ligand interactions abrogated the proliferation of malignant cells in vitro and in patient-derived xenograft. Here we demonstrate the role of lymph node tissue stiffness on DLBCL in a B-cell molecular subtype specific manner. We engineered tunable bioartificial hydrogels that mimicked the stiffness of healthy and neoplastic lymph nodes of a transgenic mouse model and primary human lymphoma tumors. Our results demonstrate that molecularly diverse DLBCLs grow differentially in soft and high stiffness microenvironments, which further modulates the integrin and B-cell receptor expression level as well as response to therapeutics. We anticipate that our findings will be broadly useful to study lymphoma biology and discover new class of therapeutics that target B-cell tumors in physical environments.

Key Words: B-cell receptor, organoids, integrin, germinal center, tissue stiffness, biomechanics, extracellular matrix, chemoresistance, contractility, DLBCL

INTRODUCTION

Despite advances in therapeutics and diagnostics, many mature B-cell lymphomas remain incurable. This is partly attributable to the genetic heterogeneity of B-cell lymphomas as well as the complex growth and survival signaling provided by the biophysical, biochemical, and cellular components of the lymphoid tumor microenvironment. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, representing ~30–40% of all B-cell non-Hodgkin’s lymphomas, and gene expression profiling has allowed sub-classification into germinal center B cell (GCB) and activated B-cell (ABC) DLBCL subtypes.1–6 The standard combination chemotherapy, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) was the frontline therapy for many years, until the addition of Rittuximab (R-CHOP). Still, a significant percentage of DLBCL patients are
not cured. Activated B-cell-like (ABC) DLBCL is the most chemo-resistant DLBCL subtype with poor 5-year overall survival compared to germinal center B-cell-like (GCB) DLBCL. Improved therapies are needed for all DLBCLs but most urgently for ABC-DLBCLs. A myriad of predictive biomarkers for resistance have been identified, including genetic and proteomic signature, stromal signatures, and somatic mutations. But none is sufficient to predict resistance in a given patient and few are helpful in guiding selection of targeted therapies. Therefore, new treatments and treatment-specific biomarkers are needed to improve clinical outcome of both ABC and GCB DLBCL patients. However, rational clinical translation requires understanding the factors that modulate expression level of BCR in lymphomas.

The microenvironment in tumors often differs from that in normal tissue, exhibiting altered composition and density of ECM proteins, stromal and immune cells, and growth factors. This altered microenvironment has been implicated as contributing to cancer development and progression for a variety of tumors. However, the role of the lymphoid tumor microenvironment, where lymphomas arise and reside, remains unclear. A major bottleneck in the field is that it remains unclear how combinations of biophysical and/or biomolecular signals that exist in close spatial and temporal order across the lymphoma tumor microenvironment affect ABC-DLBCL and GCB-DLBCL growth and response to therapies. The tumor microenvironment of B-cell lymphomas contains highly variable numbers of immune cells, stromal cells, blood vessels and an altered extracellular matrix. In the recent years, we and others have shown that the crosstalk between lymphoma cells and the extracellular matrix via integrin molecules is important for their survival and chemoresistance. Specifically, in our effort to understand the role of lymphoma microenvironment, we have recently shown that the crosstalk between the lymphoma microenvironment and integrin αvβ3 is critical for human T-cell lymphoma survival, both in vitro and in vivo. In contrast, we discovered that human ABC-DLBCLs have a differential need for integrin α4β1 and αvβ3 for survival, in a stromal follicular dendritic cell-dependent manner. We now hypothesize that extracellular matrix stiffness is another aspect of the lymph node microenvironment that can influence lymphoma fate.

For many cancers, increased extracellular matrix stiffness is associated with induction and progression of malignant phenotypes. In line with these observations and others, several bioengineered scaffolds have been developed to study the role of mechanical stiffness in tumor survival and progression. A recent study evaluated the role of 3D matrix stiffness on proliferation and drug sensitivity of human myeloid leukemia, which represent liquid tumors originating from bone marrow. However, to date, there are no reported studies on the role of tissue stiffness in lymphomas which arise and for the most part, reside in lymphoid tissues such as lymph nodes. Despite the enlargement and palpable stiffness of neoplastic lymphoid tissue typically used as an initial screen, the role of lymphoid tissue stiffness in lymphoma remains unclear. The challenge in performing these studies is lack of tunable ex vivo engineered systems that present survival signals to lymphomas and limited understanding of lymphoid tissue stiffness.

Here we quantify healthy and neoplastic lymph node (and spleen) tissue biomechanics using micropipette aspiration. This technique measures local tissue distention due to applied vacuum pressure, analogous to a uniaxial tensile test, as demonstrated by us using finite element analysis. We demonstrate that lymphoid tumors have increased tissue stiffness as compared to healthy lymph nodes and spleen. We correlated this data with independent rheology measurements, and engineered hydrogel-based organoids with physiologically or pathologically stiff matrix. We demonstrate design of biomaterials-based hydrogels with tunable mechanical stiffness for growth modulation of B-cell lymphomas, and discover that lymphomas respond differentially to soft and high stiffness microenvironments in a molecular subtype dependent manner. Engineered hydrogel-based lymphoma organoids using our previously reported immune organoids demonstrate that lymphoid-mimicking stiffness can act as an important biophysical stimulus on lymphoid tumor cells by influencing BCR and integrin expression levels, with consequences on cell survival and drug resistance, depending on the particular DLBCL molecular subtype. This is the first study, to our knowledge, that demonstrates the role of lymphoid tissue stiffness on the prosurvival surface receptors and drug response in genetically diverse B-cell lymphomas.

**MATERIALS AND METHODS**

**Tg(IghMyc)22Bri (Eμ-myc) mouse model of human lymphoma**

Tg(IghMyc)22Bri (Eμ-myc) mice on the C57BL/6J strain background were purchased from the Jackson Laboratory and maintained as hemizygotes. All animals used in this study were handled in accordance with federal and institutional guidelines, under a protocol approved by the Cornell University Institutional Animal Care and Use Committee (IACUC). Mice were monitored regularly and sacrificed upon reaching humane endpoint criteria.

**Human B- and T-cell lymphoma lines**

Lymphoma cell lines that represent a spectrum of DLBCL were used in the current study. These cell lines included: HBL-1 (ABC-DLBCL, IgM BCR dependent), LY-10 (ABC-DLBCL, IgM BCR dependent), LY-3 (ABC-DLBCL, IgM BCR independent), and LY-1 (GCB-DLBCL, IgM BCR independent). Human tonsil derived follicular dendritic cells (FDC) were used as supporting stromal cells for human lymphomas. All cells except LY-10 were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. LY-10 cells were cultured in Iscove’s Modified Dulbecco’s media (IMDM) supplemented with 20% fetal bovine serum and 1% penicillin/streptomycin. The subsequent passage of these lymphoma cells involved use of 20% conditioned media from previous culture. Deidentified, freshly isolated primary human follicular B-cell lymphoma tissue from lymph node of an untreated patient was made available by Dr. Leandro Cerchietti at Weill Cornell Medical College of Cornell University, in accordance with the Institutional Review Board guidelines.
Hydrogel fabrication and mechanical testing
A stock solution of 6% (weight/volume) gelatin (Sigma-Aldrich) in RPMI or IMDM media and stock suspension of 4% silicate nanoparticles (diameter ~25 nm and thickness ~1 nm; Southern Clay Products Inc.) was freshly prepared in sterile deionized water. We have previously shown that mixing gelatin and silicate nanoparticles results in the formation of a stable hydrogel network. Lympoma cells (12,000 per 12 μl hydrogel) were added to stock gel solution. The FDCs were mitotically inhibited through incubation in cell culture medium containing 0.01 mg/mL Mitomycin C at 37°C for 45 min in complete media conditions prior to the encapsulation. The cells were rinsed twice with 10 mL of 1× PBS before usage in the experiments. The two stock solutions were mixed together using the repeated pipetting method, as described earlier by us, to achieve a cross-linked 12 μl hydrogel organoids with (a) 2% gelatin and 2% nanoparticle, (b) 2.5% gelatin and 2% nanoparticle, and (c) 3% gelatin and 2% nanoparticle compositions. Organoids were fabricated in non-treated 96-well plates, cured for 5 min before adding growth media, which was replaced every 3 days. For stiffness measurements (storage modulus), hydrogels were analyzed using a Paar Physica MCR 300 rheometer with 50 mm flat-plate geometry under a strain history was mitigated by preconditioning with ~20 cycles of low presurization (<1 Pa). The lowest pressure that ensured stable contact with the micropipette was taken as zero pressure. Monotonically increasing pressure loads were then applied quasi-statically, with images captured at each increment at 150× magnification using a Zeiss Discovery v20 stereo microscope (Spectra Services, Inc.). The aspirated length was measured using calibrated images in NIH ImageJ. An experimental “stretch ratio,” \( \lambda = (L + r_p)/r_p \), was defined by normalizing the aspirated length to the pipette radius as previously described. The \( \Delta P \) versus \( \lambda \) curves were fit using the axial Cauchy stress for a uniaxial load of an incompressible material with an assumed exponential material law, specifically,

\[
\sigma_{yy} = \alpha C \exp \left[ \alpha \left( \frac{\lambda^2 + 2}{\lambda} - 3 \right) \left( \frac{\lambda^2}{\lambda} - 1 \right) \right]
\]

(1)

The fitting parameters \( \alpha \) and \( C \) were determined by minimizing the sum of the errors squared between Eq. (1) and the \( \Delta P \) versus \( \lambda \) data curves. The \( C \) parameter was modified using a scale factor determined from finite element simulation, reported earlier by us, \( C_{\text{mod}} = \gamma(x)C^{20} \). Strain energy density was evaluated as a metric for comparing mechanical testing data as previously described. Data was presented with representative stress response curves and strain energy density values were presented as mean ± SEM with \( n = 3 \). Statistical comparisons were performed using ANOVA with Tukey post-tests or Student’s \( t \) test, *\( p < 0.05 \).

Cellular analyses of lymphomas in organoids
Lymphoma proliferation studies were performed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega), as reported earlier by us. Typically, on days 1, 3, and 5, media was removed and organoids were washed once with PBS. CellTiter reagent was added as per manufacturer’s recommendation, and analyzed after 4 hours using a Biotek H1 Hybrid plate reader. For flow cytometry analysis, cells were harvested from organoids by means of enzymatic degradation with a collagenase solution (25 U/ml; Worthington Biosciences) for 6 hours. The degraded organoid suspension was passed through a 70 μm filter (BD Falcon) to separate the cells from any polymeric debris. The harvested cells were washed twice to remove the remaining collagenase and stained with antibodies against B-cell marker CD19, BCR IgM, integrins CD29 (β1) and CD49D (α4) at 1:500 dilutions for 1 hour at 4°C. The antibodies used for flow cytometry studies were Anti Human IgM (APC), Anti Human CD20 (FITC), Anti Human CD19 (FITC), Anti Human CD49D (APC), and Anti Human CD29 (APC), and all were purchased from eBiosciences. The stained cells were washed twice, re-suspended in equal volume of FACS buffer and analyzed using a BD Accuri C6 flow cytometer. FlowJo software was used to analyze data. For the Rho-ROCK pathway inhibition studies, lymphoma organoids were cultured in 1 nM Y-27632 reconstituted lymphoma growth media for 48 hours, followed by proliferation analysis.

Drug-induced apoptosis studies in organoids
All drug studies were performed by allowing cells to proliferate in organoids with varying stiffness or 2D cultures for 3 days under normal growth conditions followed by addition of the therapeutics. We studied two classes of drugs: a conventional chemotherapeutic vincristine (0.5 μM), which inhibits microtubule polymerization, and Panob Bastin (50 nM), a Histone Deacetylase Inhibitor (HDACi). After 48 hours of drug exposure, cells were harvested and stained with Annexin V-FITC (Biotium) and CD19 B-cell markers. Stained cells were quantified for percent apoptosis using Accuri C6 flow cytometer (BD Biosciences) and analyzed using FlowJo software.

Statistical analysis
The statistical analysis of variance (Tukey’s test for one-way ANOVA or Bonferroni correction for two-way ANOVA) was carried using GraphPad Prism software. A \( p \) values of <0.05 was considered significant. Two tail \( t \)-tests were performed
for comparison between two groups. All experiments were reproduced and performed in triplicates unless otherwise mentioned. The quantities are reported in the form of mean ± SEM.

RESULTS AND DISCUSSION
Change in physiological and mechanical properties of primary lymphoma tissues
To characterize changes in the stiffness of lymphoid tissues at the end of tumorigenesis, we first determined the change in the size of lymph nodes and spleen harvested from the Eμ-myc mouse model of human B-cell lymphoma.27 Oncogenesis in these mice is driven by the presence of a transgene containing the c-Myc gene under the control of the immunoglobulin heavy chain enhancer (Eμ) and c-Myc promoter. In these animals, c-Myc is overexpressed in B lymphoid cells, resulting in hyperproliferation of the pre-B-cell population prenatally as well as spontaneous formation of lymphoma. Nearly all Eμ-myc mice eventually develop pre-B- or B-cell lymphomas, with approximately 50% of animals developing neoplasms by 15–20 weeks of age. As indicated in Figure 1A,B, both inguinal and cervical lymph node showed marked enlargement as compared to a healthy lymph node (~10-fold larger size; 0.3 cm with tumor-bearing mice; p < 0.05). Similarly, spleen, another common lymphoid tissue for lymphomagenesis, also indicated a significant increase in tissue size as compared to healthy spleen (Figure 1A,B; p < 0.05). We further quantified the fold change in weight percentage of these enlarged tumors and observed ~25-fold increase in lymph node weight and ~8-fold increase in spleen (Fig. 1C; p < 0.05).

Previously reported mechanical properties of lymph node and spleen are technique and sample preparation dependent28,29 and therefore careful measurement of both lymphoid tissue and bioengineered synthetic matrices needs to be performed to understand its role in tumor growth. For example, Thomas and colleagues analyzed lymph nodes from B16 melanoma-bearing mice with respect to tumor stage and observed that lymph node metastasis of melanoma was associated with alterations in lymph node extracellular matrix content, increased intranodal pressures and increased lymph node tissue stiffness and viscoelasticity.28 The technique utilized in this work was indentation methods and yielded values in the range of 100–150 kPa. In contrast, magnetic resonance elastography techniques have reported stiffness of lymphoid tissues in the range of 1.5–3 kPa.29 Likewise, ultrasound elastography and indentation tests were used to determine mechanical properties of porcine cervical lymph nodes, however stiffness change in abnormal lymph nodes were not determined using these methods.30 To characterize the mechanical stiffness of lymphoid tissues and apply the same technique to engineered hydrogels, we used a micropipette aspiration method, reported earlier by us.20,21 This technique quantified the elongation of tissues aspirated inside the pipette in response to applied vacuum pressure (Figure 2A). The strain energy density was chosen as a measure of nonlinear tissue stiffness because prior studies have shown this
measurement to be less variable for soft tissues than the effective modulus.\textsuperscript{20,21} Indeed, attempts to quantify lymphoid tissue stiffness using rheology approaches did not provide meaningful results because the tissue was not fluidic (data not shown). As indicated in Figure 2B,C, the strain energy density for neoplastic mouse lymph node was a significant two-fold higher than the healthy mouse lymph node (\(p < 0.5\)). We next compared the stiffness of a primary human B-cell lymphoma tissue and observed that the stiffness was comparable to neoplastic mouse tissue (\(p > 0.05\)). No healthy human lymph node was used in the study because of the unavailability of a healthy donor.

**Biomaterials-based engineered lymphoma organoids with controlled stiffness**

Bioengineered in vitro models of several cancer types (e.g., melanoma, breast cancer, and lung cancer) have correlated soft or rigid extracellular matrix stiffness with malignant phenotypes.\textsuperscript{31,32} These results highlight that stiffness-induced alterations in cell proliferation is dependent on niche and tumor type. Mechanical properties, such as substrate rigidity, have been found to influence the proliferation of human immune cells.\textsuperscript{33} However, it remains unknown whether the tissue stiffness of lymph node has any effect on lymphomas.

Based on the observations of lymphoid tissue strain energy density, we engineered hydrogel-based lymphoma organoids with strain energy densities in the range of 1–2 J/m\(^3\) and coencapsulating lymphomas with supporting human tonsil derived follicular dendritic cells.\textsuperscript{22,23} As indicated in Figure 2D, hydrogels fabricated using 2.5\% gelatin and reinforced with 2\% nanoparticles showed strain energy density of hydrogel organoid as a function of gelatin weight %. The red oval dotted circle indicates the stiffness range for healthy lymph nodes, blue represents diseased lymph node, and green represents neoplastic splenic tissue stiffness range.
stiffness range support viability and spreading of mammalian cells. For the remainder of the studies, this storage modulus ($G'$) was used as a reference for hydrogel organoid stiffness and to study the role of tissue stiffness on lymphoma growth and protein expression levels.

Organoid stiffness regulate the proliferation of human lymphomas and survival of primary murine lymphomas

We first determined the role of tissue stiffness on human and mouse lymphoma growth. These studies were performed with and without stromal support. For human lymphomas, follicular dendritic cells (FDCs) were used as a stromal support as reported earlier by us. We hypothesized that the stiffness of lymphoid tissue will modulate the proliferation of lymphoma cells through mechanical stimulation of surface receptors such as integrins and BCR, and possibly through actin-mediated contractility which is known to be influenced by the extracellular matrix stiffness. In these studies, we first examined the role of organoid stiffness on the growth of IgM BCR-dependent ABC-DLBCL cell lines (Fig. 3A) and IgM-BCR independent ABC-DLBCL line OCI-LY3. In both ABC-DLBCL subtypes,

---

**FIGURE 3.** Lymphoid stiffness regulates proliferation of mature B-cell lymphomas. (A–C) Proliferation of ABC-DLBCL lines (LY-10, LY-3, and HBL-1) and GCB-DLBCL line LY-1 in hydrogel organoids, cocultured with follicular dendritic cells (FDCs). Proliferation was quantified with MTS assay, with FDCs pretreated with mitomycin C (mean ± SEM, $n = 3$, *$p < 0.05$). (D) Fluorescence microscopy projections represent live/dead population of ABC- and GCB-DLBCLs encapsulated within 2000 Pa hydrogels. Images are representative of $n = 3$. Arrows represent dead cells. Scale bar 10 μm. (E) Proliferation of ABC-DLBCL and GCB-DLBCL in 2000 Pa hydrogel organoids, cocultured with or without follicular dendritic cells (FDCs). Proliferation was quantified with MTS assay, with FDCs pretreated with mitomycin C (mean ± SEM, $n = 3$, *$p < 0.05$). (F) Proliferation of primary Eμ-myc lymphomas in 2000 Pa hydrogel organoids or 2D, cocultured with HS-5 bone marrow stromal cells. Proliferation was quantified with MTS assay, with HS-5 cells pretreated with mitomycin C (mean ± SEM, $n = 3$, *$p < 0.05$).
we observed increased growth in all organoids over 5 days of culture and the growth was significantly higher than conventional 2D cultures of lymphoma (Fig. 3A, p < 0.05). Importantly, ABC-DLBCLs grown in organoids with medium tissue stiffness (2000 Pa) showed the maximum proliferation as compared to lower stiffness (1500 Pa) and higher stiffness (3000 Pa) organoids. Importantly, the stiffness of the organoid with maximum proliferation was comparable to that of human lymphoma tissue and mouse neoplastic lymph nodes (Figure 2), suggesting that tissue stiffness supports lymphoma growth. When GCB-DLBCL cells, which are IgM-BCR independent, were cultured in the lymphoma organoids, we observed no differences in proliferation rate between 2D and 3D organoid groups (Fig. 3B), suggesting that GCB-DLBCL are either less dependent or independent of lymphoid tissue stiffness. Stiffness-dependent proliferation of ABC-DLBCL was further confirmed with another human ABC-DLBCL line HBL-1 (Fig. 3C), which demonstrated significantly higher proliferation over 4 days of culture in organoids with 2000 Pa stiffness (p < 0.05). We observed no differences in survival of ABC or GCB-DLBCLs in 3D organoids as compared to 2D cultures, as indicated by live dead staining in Figure 3D. These studies further highlight an important observation that there exists an optimum tissue stiffness at which lymphomas proliferate, which is distinct from the observations with tumors of non-lymphoid origin such as mammary tumors where increasing stiffness correlates with tumor growth. The reasons for these observations are not entirely clear and may be dependent on other phenotypic changes in these cells. Therefore, future ex vivo and in vivo studies are needed to understand the mechanism behind lower proliferation in 3000 Pa organoids.

We next determined the role of FDCs on the growth of ABC-DLBCL and GCB-DLBCL in organoids with similar mechanical stiffness to patient tissue. In ABC-DLBCL, presence of growth-arrested FDCs supported significantly higher lymphoma proliferation as compared to organoids that did not contain follicular dendritic cells (Fig. 3E, p < 0.05). These differences were not observed in 2D cocultures. Unlike ABC-DLBCLs, GCB-DLBCLs did not show any significant differences between organoids and 2D cultures, with or without FDCs (Fig. 3D). These studies further indicate that GCB-DLBCLs are less dependent on lymphoid tumor microenvironment than ABC-DLBCL.

We next determined the role of 2000 Pa hydrogel stiffness on the survival of primary Eµ-myc lymphomas in organoids as compared to 2D cocultures. Previous studies have shown that bone marrow stromal cells are critical for the survival of primary Eµ-myc lymphomas. We screened HS-5 bone marrow stromal cells which sustain hematopoiesis, our previously reported 40LB stromal cells that present mouse CD40 Ligand and B-cell activating factors, JAWSII mouse dendritic cells, and human follicular dendritic cells for sustaining the short term survival of primary Eµ-myc lymphomas. Only HS-5 sustained the survival of primary Eµ-myc lymphomas (data not shown) and therefore we used HS-5 stromal cells in 3D organoids. As indicated in Figure 3F, 2000 Pa hydrogel stiffness resulted in significantly higher survival of Eµ-myc cells as compared to 2D cells (p < 0.05). These findings suggest that matching the appropriate soft tissue stiffness and supporting stromal cells is important for prolonging the survival and growth of primary and established lymphomas.

**Stiffness promotes drug resistance against standard chemotherapy and Histone Deacetylase inhibitor**

Since most studies to date have focused on drug-lymphoma interactions under 2D conditions, we hypothesized that increased proliferation under the effect of lymphoid tissue stiffness will reduce the apoptosis of ABC-DLBCLs when exposed to anti-lymphoma drugs. In separate experiments, we exposed ABC- and GCB-DLBCLs to either the conventional chemotherapy drug vincristine or a Histone Deacetylase inhibitor (HDACi) Panobinostat. (A) Bar graphs represent % apoptosis in B-cell lymphomas exposed to vincristine. ABC-DLBCL cell lines HBL-1 and LY-3, and GCB-DLBCL cell line LY-1 were cultured for 3 days in 2D or 3D organoids and exposed to 1 nM vincristine for 48 hours. B-cell lymphomas were stained with APC-IgM BCR and Annexin V-FITC for apoptosis analysis (mean ± SEM, n = 3, *p < 0.05 compared to all 3D groups and **p < 0.05 compared to all other 3D groups). (B) Bar graphs represent % apoptosis in IgM BCR dependent ABC-DLBCL cell line HBL-1 exposed to HDACi Panobinostat. HBL-1 was cultured for 3 days in 2D cultures or 3D organoids and exposed to 50 nM Panobinostat for 24 hours. B-cell lymphoma cells were stained with CD19 and Annexin V-FITC for apoptosis analysis (mean ± SEM, n = 3, *p < 0.05 compared to all 3D groups and **p < 0.05 compared to all other 3D and 2D groups).
in a phase II B study, 48 24% of refractory cutaneous T-cell lymphoma (CTCL) patients who had originally failed conventional therapies had a complete or partial response to vorinostat, an FDA approved HDACi. Another drug of interest is Panobinostat that has been tested in hematological malignancies such as acute myeloid leukemia (AML)49 and multiple myeloma.50,51 We have previously shown that Panobinostat induces less apoptosis in lymphomas when they are treated with the drug in a tumor-specific microenvironment, such as in the presence of pro-survival integrin binding ligands17; however, not much is known about the drug response in B-cell lymphomas in the context of tissue stiffness.

As indicated in Figure 4A,B, when exposed to either vincristine or Panobinostatin, a significant 20–40% lower Annexin-V staining (apoptosis) was observed in HBL-1 cells grown in 3D organoids of varying stiffness as compared to 2D growth conditions. Organoids with tissue stiffness (2000 Pa) comparable to human lymphoma tissue stiffness demonstrated maximum resistance to apoptosis within organoid groups (resistance: 1500 < 2000 > 3000 Pa). Since HBL-1 is IgM BCR-dependent ABC-DLBCL, we further determined the effect of these drugs on a BCR-independent ABC-DLBCL to better understand the relationship between drug response and BCR signaling. Unlike HBL-1 ABC-DLBCLs, BCR independent LY3 showed the lowest apoptosis in the softest organoids instead of an organoid with intermediate stiffness, although all organoids demonstrated significant lower apoptosis than in 2D growth conditions (resistance: 1500 > 2000 Pa = 3000 Pa). Similar to ABC-DLBCLs, we observed reduced apoptosis in GCB-DLBCL OCI-LY1 cells grown in 3D organoids; however we did not observe any difference in drug resistance between the soft and stiff organoids.

These observations support the proliferation results where ABC-DLBCL proliferation was dependent on organoid stiffness, whereas GCB-DLBCL proliferation was independent of stiffness. We do not anticipate drug diffusion to be responsible for these differences because these organoids have been previously used for cytokine delivery and antibody staining.22 The general reduction in apoptosis observed in 3D microenvironment as compared to classic 2D cultures are consistent with our previous reported work, where similar drug uptake was observed under both 3D and 2D conditions.17 Instead, we hypothesize that reduced apoptosis in the 3D organoid microenvironment can be attributed to differential regulation of pro-survival signals such as integrin receptors and BCR on these cells. To test this hypothesis, we evaluated the expression level of hallmark markers CD19 and BCR on the surface of cells either grown in 2D or in 3D organoids with varying stiffness. As indicated in Figure 5A, IgM-dependent ABC-DLBCL (HBL-1) upregulated the expression level of CD19 in 3D organoids as compared to 2D cultures, and maximum CD19 expression level was observed at 2000 Pa stiffness. Similar observations were made with IgM-independent ABC-DLBCL cell line LY-3. In contrast, while GCB-DLBCLs, 2000 Pa stiff hydrogels demonstrated maximum upregulation of IgM-BCR whereas in LY-3, 2000 Pa stiffness significantly reduced IgM expression level between the three organoid stiffness. There was no effect of stiffness in LY-1 GCB-DLBCL, and all 2D cultures had lower expression levels of IgM-BCR.

FIGURE 5. Effect of lymphoid tissue stiffness on B-cell lymphoma markers and B-cell receptor. (A and B) Bar graphs represent flow cytometry analysis (mean fluorescence intensity (MFI)) of (A) CD19 and (B) IgM surface markers in ABC- and GCB-DLBCL cells cultured in 2D condition or 3D organoids (all with FDCs) (mean ± SEM, n = 3, *p < 0.05, ANOVA and #p < 0.05 compared to all other 3D groups).
This observation is important because in ABC-DLBCLs, IgM BCR is chronically activated and has implications in lymphoma survival and progression.\textsuperscript{1,52} The BCR is a transmembrane protein complex located on the outer surface of healthy and malignant B cells.\textsuperscript{52} It is a heterodimer composed of heavy-chain and light-chain immunoglobulins (Igs), CD79A/Ig\textsubscript{a}, and CD79B/Ig\textsubscript{b}. ABC-DLBCLs are commonly associated with mutations of components in the BCR pathway, such as CD79A/B (\textasciitilde20\% of ABC-DLBCLs),\textsuperscript{5} CARD11 (\textasciitilde10\%),\textsuperscript{6} and several others. Targeting hallmark pathways of ABC-DLBCL, such as those activated by the BCR, has the potential to impact a broad cross-section of ABC-DLBCL patients.\textsuperscript{53,54}

Proposed therapeutic strategies for ABC-DLBCL target proteins that signal downstream of the BCR pathway, including kinase inhibitors targeting Bruton’s tyrosine kinase (BTK), mitogen-activated protein kinases (MAPKs), and AKT.\textsuperscript{1} These signaling mediators intersect with integrins such as $\alpha$4$\beta$1, and other mechano-transduction pathways,\textsuperscript{55–57} which can be activated through adhesion to extracellular matrix and tissue stiffness. Therefore, we next determined the expression level of integrin $\beta$1 in human lymphomas and primary mouse lymphomas. As indicated in Figure 6, integrin $\beta$1 mean fluorescent intensity was significantly higher in 2000 Pa organoids in both IgM-dependent and –independent ABC-DLBCLs ($p < 0.05$). In contrast, expression level of integrin $\beta$1 in GCB-DLBCL was higher in the softest organoid (1500 Pa) and not in intermediate 2000 Pa organoids. Since previous studies have shown that integrin $\beta$1 supports survival and growth of ABC-DLBCLs, this current study suggests that the stiffness of lymphoid tissue can upregulate the expression level of mechanoreceptor integrin $\beta$1 in ex vivo cultures. We further observed an increase in integrin $\beta$1 expression in primary E\textsubscript{L}-Myc lymphomas as well, as compared to 2D cocultures, a finding that supports the need for modular 3D lymphoma tissue constructs with tunable stiffness for supporting primary and established lymphoma cultures. We used the 2000 Pa stiffness to compare differences in expression levels of IgM BCR in primary lymphoma tissues when cultured in 3D versus 2D conditions. We cultured E\textsubscript{L}-Myc tumors with HS-5 in 2D cocultures and 3D organoids, and observed a significant increase in IgM-BCR levels (Figure 7), which suggested that 3D organoids modulated the expression levels of surface markers in primary mouse tumors.

Stiffness and deformation of extra cellular matrix are strongly regulated by actomyosin contractility.\textsuperscript{39} Because...
our results indicated that the expression levels of integrin β1 in lymphomas were regulated by matrix stiffness and since previous studies have shown that integrin β1 is linked to the actin cytoskeleton via association with proteins such as talin and vinculin, 58–60 we hypothesized that the enhanced growth of lymphomas in 2000 Pa organoids could be attributed to integrin-actin-mediated contractility. We therefore inhibited actin-myosin contractility using a Rhodocyclin inhibitor (Y-27632). 55,61 As indicated in Figure 8, inhibiting contractility did not affect ABC-DLBCLs in 2D cultures, but significantly reduced proliferation in 2000 Pa 3D organoids. This effect was not observed in GCB-DLBCL, which suggested that contractility mediated proliferation was specific to ABC-DLBCL.

CONCLUSION

Our results are the first evidence that lymphoma survival, proliferation, drug response, and BCR signaling is influenced by lymphoid tissue stiffness in a molecular subtype dependent manner. These results emphasize the role of tumor stiffness matched biomaterial organoids and lymphoid tissue stiffness in progression and drug response of malignant B-cell tumors. In the past, lymphoid tissue stiffness and mechanosensing has been largely ignored in mechanistic study of lymphoma progression and its therapeutic evaluation of B-cell lymphomas ex vivo. Therefore, investigation of chemotherapeutics and upcoming new classes of therapeutic agents that target epigenetic, matrix, or angiogenesis pathways should consider the potential confounding interactions between the lymphoid tumor microenvironment and cell-molecular level. Future studies will determine the independent role of tissue bioadhesive signals, stiffness, 9,10 and stress relaxation 42 in the proliferation and drug response in lymphomas and may require modular biomaterials with controlled presentation of these biophysical stimuli. 63,64

ACKNOWLEDGMENTS

The authors thank Dr. Jude Phillip at Weill Cornell Medical College of Cornell University for handling primary human lymphoma tissue and Yashira Negron Abirr for assistance with Ep-Myc mouse genotyping. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

REFERENCES

44. Butcher JT, McQuinn TC, Sedmera D, Turner D, Markwald RR. Transitions in early embryonic atrioventricular valvular function correspond with changes in cushion biomechanics that are predictable by tissue composition, Circ Res 2007;100:1503–11.